Carregant...

Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer

IMPORTANCE: The BEACON trial showed that combination therapy with encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) was associated with prolonged overall survival compared with standard chemotherapy in patients with metastatic BRAF variant colorectal cancer. However, the cost-effectiveness...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Netw Open
Autors principals: Patel, Kishan K., Stein, Stacey, Lacy, Jill, O’Hara, Mark, Huntington, Scott F.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2021
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7804917/
https://ncbi.nlm.nih.gov/pubmed/33433598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.33441
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!